Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia

Blood

Volumn 101, Issue 2, 2003, Pages 524-531

  Jacobs Helber, Sarah M ^a   Roh, Kwan ho ^a   Bailey, Daniel ^a   Dessypris, Emmanuel N ^a   Ryan, John J ^a   Chen, Jingchun ^a   Wickrema, Amittha ^a   Barber, Dwayne L ^a   Dent, Paul ^a   Sawyer, Stephen T ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; ERYTHROPOIESIS; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 0037438503     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-11-0084     Document Type: Article

References (61)

1. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors: role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem. 1996;271:32430-32437.
2. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993; 74:227-236.
3. Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood. 1994;84: 1501-1507.
4. Barber DL, D'Andrea AD. Erythropoietin and interleukin-2 activate distinct JAK kinase family members. Mol Cell Biol. 1994;14:6506-6514.
5. Damen JE, Mui AL, Pull JL, Pawson T, Krystal G. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood. 1993;81:3204-3210.
6. He TC, Zhuang H, Quelle DE, Wojchowski DM. Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain. Blood. 1993;82: 3530-3538.
7. Damen JE, Liu L, Cutler RL, Krystal G. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein. Blood. 1993;82: 2296-2303.
8. He TC, Jiang N, Zhuang H, Wojchowski DM. Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway. J Biol Chem. 1995;270: 11055-11061.
9. Barber DL, Corless CN, Xia K, Roberts TM, D'Andrea AD. Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. Blood. 1997;89:55-64.
10. Damen JE, Liu L, Rosten P, et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci U S A. 1996;93:1689-1693.
11. Boer AK, Drayer AL, Vellenga E. Effects of overexpression of the SH-2-containing inositol phosphatase SHIP on proliferation and apoptosis of erythroid AS-E2 cells. Leukemia. 2001;15:1750-1757.
12. Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood. 2000;96:933-940.
13. Nagata Y, Nishida E, Todokoro K. Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood. 1997;89: 2664-2669.
14. Jacobs-Helber SM, Penta K, Sun ZH, Lawson A, Sawyer ST. Distinct signaling from stem cell factor and erythropoietin in HCD57 cells. J Biol Chem. 1997;272:6850-6853.
15. Devemy E, Billat C, Haye B. Activation of Raf-1 and mitogen-activated protein kinases by erythropoietin and inositolphosphate-glycan in normal erythroid progenitor cells: involvement of protein kinase C. Cell Signal. 1997;9:41-46.
16. Nagata Y, Takahashi N, Davis RJ, Todokoro K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood. 1998;92:1859-1869.
17. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood. 1999;94:853-863.
18. Lawson AE, Bao H, Wickrema A, Jacobs-Helber SM, Sawyer ST. Phosphatase inhibition promotes antiapoptotic but not proliferative signaling pathways in erythropoietin-dependent HCD57 cells. Blood. 2000;96:2084-2092.
19. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 2000;95:2391-2396.
20. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996; 334:1717-1725.
21. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-367.
22. Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines. J Biol Chem. 2000;275:21086-21093.
23. Witsell AL, Schook LB. Tumor necrosis factor alpha is an autocrine growth regulator during macrophage differentiation. Proc Natl Acad Sci U S A. 1992;89:4754-4758.
24. Branch DR, Guilbert LJ. Autocrine regulation of macrophage proliferation by tumor necrosis factor-alpha. Exp Hematol. 1996;24:675-681.
25. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma. 1996;22: 83-90.
26. Moberts R, Hoogerbrugge H, van Agthoven T, Lowenberg B, Touw I. Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumor necrosis factors alpha and beta. Leuk Res. 1989;13:973-980.
27. Marth C, Zeimet AG, Herold M, et al. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer. 1996;67:826-830.
28. Quentmeier H, Dirks WG, Fleckenstein D, Zaborski M, Drexler HG. Tumor necrosis factor-alpha-induced proliferation requires synthesis of granulocyte-macrophage colony-stimulating factor. Exp Hematol. 2000;28:1008-1015.
29. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989;3:1637-1643.
30. Akahane K, Hosoi T, Urabe A, Kawakami M, Takaku F. Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int J Cell Cloning. 1987;5:16-26.
31. Ulich TR, del Castillo J, Yin S. Tumor necrosis factor exerts dose-dependent effects on erythropoiesis and myelopoiesis in vivo. Exp Hematol. 1990;18:311-315.
32. Means RT Jr, Dessypris EN, Krantz SB. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest. 1990;86:538-541.
33. Means PIT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest. 1993; 91:416-419.
34. Snoeck HW, Weekx S, Moulijn A, et al. Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma. J Exp Med. 1996;183:705-710.
35. Jacobs-Helber SM, Wickrema A, Birrer MJ, Sawyer ST. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol. 1998;18:3699-3707.
36. Angchaisuksiri P, Grigus SR, Carlson PL, Krystal GW, Dessypris EN. Secretion of a unique peptide from interleukin-2-stimulated natural killer cells that induces endomitosis in immature human megakaryocytes. Blood. 2002;99:130-136.
37. Penta K, Sawyer ST. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem. 1995;270:31282-31287.
38. Miura O, Ihle JN. Subunit structure of the erythropoietin receptor analyzed by 1251-Epo cross-linking in cells expressing wild-type or mutant receptors. Blood. 1993;81:1739-1744.
39. Carroll M, Zhu Y, D'Andrea AD. Erythropoietin-induced cellular differentiation requires prolongation of the G1 phase of the cell cycle. Proc Natl Acad Sci U S A. 1995;92:2869-2873.
40. Bondurant M, Koury M, Krantz SB, Blevins T, Duncan DT. Isolation of erythropoietin-sensitive cells from Friend virus-infected marrow cultures: characteristics of the erythropoietin response. Blood. 1983;61:751-758.
41. Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol. 1990;18:109-113.
42. + progenitors. Exp Hematol. 1995;23:551-556.
43. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood. 1995;85:989-996.
44. Jacobsen FW, Rothe M, Rusten L, et al. Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis. Proc Natl Acad Sci U S A. 1994;91:10695-10699.
45. Otsuki T, Nagakura S, Wang J, Bloom M, Grompe M, Liu JM. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol. 1999;179:79-86.
46. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
47. Schultz JC, Shahidi NT. Detection of tumor necrosis factor-alpha in bone marrow plasma and peripheral blood plasma from patients with aplastic anemia. Am J Hematol. 1994;45:32-38.
48. Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med. 1999;47: 204-211.
49. Jongen-Lavrencic M, Peeters HR, Backx B, Touw IP, Vreugdenhil G, Swaak AJ. R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis. Rheumatol Int. 1994;14:109-113.
50. Muszynski KW, Ohashi T, Hanson C, et al. Both the polycythemia and anemia-inducing strains of Friend spleen focus-forming virus induce constitutive activation of Raf-1/mitogen-activated protein kinase signal transduction pathway. J Virol. 1998;72:919-925.
51. + cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001;97:3075-3085.
52. Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-α in rat mesangial cells. J Biol Chem. 1998;273:4027-4034.
53. Sanna MG, da Silva CJ, Ducrey O, et al. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol. 2002;22:1754-1766.
54. Rogers JA, Berman JW. TNF-alpha inhibits the further development of committed progenitors while stimulating multipotential progenitors in mouse long-term bone marrow cultures. J Immunol. 1994;153:4694-4703.
55. Jacobs-Helber SM, Abutin RM, Tian C, Bondurant M, Wickrema A, Sawyer ST. Role of JunB in erythroid differentiation. J Biol Chem. 2002;277: 4859-4866.
56. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274: 784-787.
57. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 1996;87:565-576.
58. Manna SK, Haridas V, Aggarwal BB. Bcl-x(L) suppresses TNF-mediated apoptosis and activation of nuclear factor-kappaB, activation protein-1, and c-Jun N-terminal kinase. J Interferon Cytokine Res. 2000;20:725-735.
59. Spivak JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and a survival factor. Blood. 1991;77:1228-1233.
60. Zermati Y, Fichelson S, Valensi F, et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. 2000; 28:885-894.
61. Zermati Y, Varet B, Hermine O. TGF-beta1 drives and accelerates erythroid differentiation in the epo-dependent UT-7 cell line even in the absence of erythropoietin. Exp Hematol. 2000;28:256-266.